Inclusion body myositis — a case based clinicopathological update

Levente Bodoki 1 , Melinda Vincze 1 , Zoltán Griger 1 , Tamás Csonka 2 , Balázs Murnyák 2 , Andrea Kurucz 2 , Katalin Dankó 1 , and Tibor Hortobágyi 2
  • 1 Institute of Internal Medicine, Third Department of Internal Medicine, Division of Clinical Immunology, University of Debrecen Medical & Health Science Centre, Debrecen, Hungary
  • 2 Institute of Pathology, Department of Neuropathology, University of Debrecen Medical and Health Science Centre, Debrecen, Hungary


Inclusion body myositis is a slowly progressive myopathy affecting predominantly the middle-aged and older patient population. It is a major form of the idiopathic inflammatory myopathies which are chronic systemic autoimmune diseases characterized by symmetrical proximal muscle weakness. Unfortunately, there is no effective therapy yet; however, the early diagnosis is essential to provide treatment options which may significantly slow the progression of the disease. In our case-based clinicopathological study the importance of the close collaboration between the clinician and the neuropathologist is emphasised.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • [1] Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292:344–347

  • [2] Benveniste O. et al. International Workshop on Inclusion Body Myositis held at the Institute of Myology, Paris, on 29 May 2009. Neuromuscul Disord. 2010;20:414–421

  • [3] Greenberg SA. Pathogenesis and therapy of inclusion body myositis. Curr Opin Neurol. 2012;25:630–639

  • [4] Askanas V. et al. Sporadic inclusion-body myositis: conformational multifactorial ageing-related degenerative muscle disease associated with proteasomal and lysosomal inhibition, endoplasmic reticulum stress, and accumulation of amyloid-β42 oligomers and phosphorylated tau. Presse Med. 2011;40(4 Pt 2):e219–235

  • [5] Murnyák B., and Bodoki L. et al. Inclusion body myositis — pathomechanism and lessons from genetics 2013. (Cent Eur J Med. 2013 submitted for publication)

  • [6] Greenberg SA. Theories of the pathogenesis of inclusion body myositis. Curr Rheumatol Rep. 2010;12:221–228

  • [7] Váncsa A. et al. [Inclusion body myositis pathomechanism and therapy]. [Article in Hungarian]. Orv Hetil. 2008;149:1413–1418

  • [8] Quick A. et al. Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease. Curr Rheumatol Rep. 2011;13:192–198

  • [9] Kierdaszuk B. et al. Inclusion body myositis: therapeutic approaches. A case report. Neurol Neurochir Pol. 2011;45:68–73

  • [10] Dziadzio M. et al. Common variable immunodeficiency with coexisting central nervous system sarcoidosis. Case report and literature review with implications for diagnosis and pathogenesis. Ideggyogy Sz 2011;64:405–408

  • [11] Csonka T. et al. The diagnosis of herpes encephalitis- a case-based update. Ideggyogy Sz 2013 (in press)

  • [12] Rider LG. et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken). 2010 Apr;62(4):465–72. doi: 10.1002/acr.20035

  • [13] Kendall FP. Et al. Muscles: testing and function. 4th ed. Baltimore: Williams and Wilkins; 1993

  • [14] Rider LG. et al. International Myositis Assessment and Clinical Studies Group, International Consensus On Preliminary Definitions of Improvement for Adult and Juvenile Myositis, Arthritis Rheum., 2004 Jul, 50(7):2281–2290

  • [15] Cox FM. et al. Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology (Oxford). 2011;50:1153–1161


Journal + Issues